Clinical Nuclear Medicine

Skip Navigation LinksHome > May 2013 - Volume 38 - Issue 5 > Distinguishing Pseudoprogression From Progression in High-Gr...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e318286c148
Interesting Images

Distinguishing Pseudoprogression From Progression in High-Grade Gliomas: A Brief Review of Current Clinical Practice and Demonstration of the Potential Value of 18F-FDG PET

Oborski, Matthew J. MS*; Laymon, Charles M. PhD*; Lieberman, Frank S. MD; Mountz, James M. MD, PhD*

Collapse Box


Abstract: We report a case in which 18F-FDG PET was able to discriminate pseudoprogression from progression observed on contrast-enhanced (CE) MRI (CE-MRI). A 56-year-old male patient with anaplastic oligodendroglioma demonstrated markedly increased tumor enhancement on CE-MRI 1 month after completing radiation therapy (RT), suggesting radiological progression. However, the patient was clinically improved and therefore received an early-therapy response assessment PET to assess for pseudoprogression. PET showed low tumor uptake indicating stable disease. Follow-up CE-MRI at 3 and 4 months post-RT confirmed stable disease. This case emphasizes the value of 18F-FDG PET when pseudoprogression is clinically suspected.

© 2013 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.